Dokumente
Suchschritt : FT=glucosamine AND FT=osteoarthritis
» Fenster schließen »

2/360 von 416 DIMDI: MEDLINE (ME60) © NLM

ND: | ME09140889
PMID: | 9140889
LR: | 20061115
CED: | 19970707
DCO: | 19970707
Autoren: | McCarty MF
Titel: | Glucosamine may retard atherogenesis by promoting endothelial production of heparan sulfate proteoglycans.
Quelle: | Medical hypotheses; VOL: 48 (3); p. 245-51 /199703/
PM: | Print
SU: | IM
Sprache: | English
CY: | ENGLAND
JID: | 7505668
ISSN: | 0306-9877
CO: | MEHYDY
Institution: | Nutrition 21, San Diego, CA 92109, USA.
DT: | Journal Article; Review
RN: | 94
Schlagwörter
CT: | ANIMALS; ARTERIOSCLEROSIS/physiopathology; ARTERIOSCLEROSIS/*prevention & control; CARTILAGE/drug effects; CARTILAGE/metabolism; CELLS, CULTURED; CORONARY DISEASE/drug therapy; ENDOTHELIUM, VASCULAR/drug effects; ENDOTHELIUM, VASCULAR/*metabolism; FIBROBLASTS/drug effects; FIBROBLASTS/metabolism; GLUCOSAMINE/*pharmacology; GLUCOSAMINE/*therapeutic use; GLYCOSAMINOGLYCANS/biosynthesis; HEPARAN SULFATE PROTEOGLYCANS; HEPARIN/therapeutic use; HEPARITIN SULFATE/*biosynthesis; HUMANS; MODELS, CARDIOVASCULAR/*; PROTEOGLYCANS/*biosynthesis
CTG: | TIER; ARTERIOSKLEROSE/Pathophysiologie; ARTERIOSKLEROSE/*Verhütung & Bekämpfung; KNORPEL/Arzneimittelwirkungen; KNORPEL/Stoffwechsel; ZELLEN, KULTIVIERTE; KORONARKRANKHEIT/Arzneimitteltherapie; ENDOTHEL, GEFÄß-/Arzneimittelwirkungen; ENDOTHEL, GEFÄß-/*Stoffwechsel; FIBROBLASTEN/Arzneimittelwirkungen; FIBROBLASTEN/Stoffwechsel; GLUCOSAMIN/*Pharmakologie; GLUCOSAMIN/*therapeutische Anwendung; GLYCOSAMINO-GLYCANE/Biosynthese; HEPARANSULFAT-PROTEOGLYCAN; HEPARIN/therapeutische Anwendung; HEPARITINSULFAT/*Biosynthese; MENSCH; MODELLE, KARDIOVASKULÄRE/*; PROTEOGLYCANE/*Biosynthese
TE: | Glycosaminoglycans; Heparan Sulfate Proteoglycans; Proteoglycans; Glucosamine/3416-24-8; Heparin/9005-49-6; Heparitin Sulfate/9050-30-0
CR: | 3416-24-8; 9005-49-6; 9050-30-0
AB: | Heparan sulfate proteoglycans produced by vascular endothelium may function physiologically to restrain the migration, multiplication, and phenotypic transition of vascular smooth-muscle cells, and to maintain an anticoagulant luminal surface by bonding and activating antithrombin III. Thus, ample production of heparan sulfate proteoglycans may act to prevent atherosclerosis and its thrombotic complications. The ability of exogenous heparin to stimulate synthesis of heparan sulfate proteoglycans by vascular endothelium may be largely responsible for the positive outcomes of most controlled evaluations of low-dose heparin as a long-term therapy for coronary disease. Glucosamine, a biosynthetic precursor of mucopolysaccharides, can substantially enhance mucopolysaccharide production when added to cultured fibroblasts or chondrocytes; the clinical utility of oral glucosamine in osteoarthritis may reflect increased synthesis of cartilage proteoglycans. It is reasonable to speculate that exogenous glucosamine will likewise enhance heparan sulfate proteoglycans production by vascular endothelial cells, and, when administered orally in regimens comparable to those effective in osteoarthritis, will thereby act to retard atherogenesis.

» Volltext »
» Fenster schließen »